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January 8, 2013:108–11ation functional class using the PARTNER (Placement of Aortic
Transcatheter Valves) data, but we would expect them to move in
directionally similar ways, particularly for measures such as the
physical component score of the SF-12 or SF-36. Longer term
quality-of-life data from the PARTNER program are being
collected but are not yet available for analysis. In the meantime,
New York Heart Association data through 2 years have been
reported for both the inoperable (2) and high-risk surgical candi-
date populations (3). These reports show that about 85% of 2-year
survivors were in New York Heart Association functional class I or
II after either transcatheter aortic valve replacement (TAVR) or
aortic valve replacement, with no suggestion of deterioration from
year 1 to year 2. However, these analyses of survivors may be
affected by attrition of the sickest patients over time. Given the age
and medical complexity of patients currently undergoing TAVR, it
would not be surprising to see some decline in functional status
and quality of life over time, as observed with aging in general, and
as suggested in a UK analysis of TAVR patients limited to those
who completed surveys at all 4 time points in the first year (4). We
agree that the identification of baseline patient factors that reliably
predict changes in health status after TAVR (or aortic valve
replacement) would aid in refining patient selection for these
interventions and should be the focus of subsequent investigations.
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Outcomes of Atrial Fibrillation
Ablation in Patients With
Metabolic Syndrome
We read with interest the paper by Mohanty et al. (1), which
demonstrates a strong association between metabolic syndrome(MS) and recurrence of atrial fibrillation after catheter ablation
(AFCA) but only in patients with nonparoxysmal atrial fibrillation
(NPAF).
Recently, we presented the data of 5-year follow-up in a group
of 702 patients after both radiofrequency and cryoballoon AFCA
that proved MS to be the independent predictor of atrial fibrilla-
tion (AF)-free survival AFCA, regardless of left atrium size (LAS),
type of AF, and energy source used (2). Patients with MS were
1.32 more likely to have AF recurrence than patients without
MS. Median time to AF recurrence AFCA was 18.6 months in
patients with MS and 28.6 months in patients without MS
(p  0.011) (Fig. 1). Similar results were published by others
3,4), and the discrepancy had already been mentioned by Asir-
vatham and Jiao (5). Interestingly, our data showed that MS had
no impact on outcome after re-do pulmonary vein isolation, which
might support the editorial comment: “perhaps we learned that
trigger elimination, even if in 1-time procedure, can be effective
despite an ongoing primary arrhythmia-provoking process” (5).
The contradictory findings by Mohanty et al. (1) might be
in part) explained by several limitations of their study. First, the
resented study group was not as homogenous as ours, with
ignificant differences in LAS and upstream therapy drugs. The
AS is known to be one of the strongest predictors of outcome
fter AF ablation (6). If LAS was significantly bigger in NPAF
ithout MS, the expected results could have been as described by
nvestigators (1). Renin-angiotensin-aldosterone system blockers
protect from AFCA in patients with PAF (7). Most of the patients
with MS (82%) received angiotensin-converting enzyme inhib-
itors compared with patients without MS (28%). If the similar
proportion was in the PAF group, we could have expected
better outcome in patients with MS (i.e., no significant differ-
ence as described) (1). The role of statins post-pulmonary vein
solation has not been established (6), but the published
meta-analysis reported statins to be more effective for preven-
tion of PAF (8). Again, a higher number of patients with MS
91%) received lipid-lowering therapy than patients without
S (30%). Second, the results should be checked—keeping in
ind the noncompletely homogenous study group—with a
ropensity score matching, which allows for analysis in a
ell-balanced cohort. It would be interesting to know whether
ohanty et al. (1) would reach the same results in the
well-matched samples. Third, the follow-up period was (only)
21  7 months. The difference in the outcome AFCA in patients
with and without MS becomes even more significant within longer
follow-up, both in PAF and NPAF groups (2).
Following the latest recommendations (6), we think that it is
important to recognize that AF recurrence rates AFCA depend on
concomitant diseases, and outcome of AFCA in patient popula-
tions not well-represented in clinical trials should be reported.
Patients with MS are such a population. Therefore, further
discussion and clear data presentation are needed to solve the
discrepancy in reported results.
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Reply
We thank Dr. Wojcik and colleagues for their interest in our
study (1).
The apparent contradiction between our findings and their
results can be explained by at least 3 factors: difference in study
population, detection and elimination of nonpulmonary vein
(non-PV) triggers, and use of discretion of the physician in patient
selection.
Our population had predominantly nonparoxysmal atrial fibril-
lation (NPAF), compared with theirs. Most importantly, we
observed in the NPAF cohort significantly more frequent non-PV
triggers in the metabolic syndrome (MS) group compared with the
non-MS group, which is in accordance with earlier studies by
others (2). As we discussed in our study, the challenge of
eliminating non-PV triggers could have contributed to the higher
atrial tachycardia after the first procedure in patients with
lic syndrome; Non MetS  patients without metabolic syndrome.AF) or
etaborecurrence in the MS group of the NPAF cohort. Of note,
